Salix Pharmaceuticals Inc.
- Address
- 400 Somerset Corporate Boulevard
Sponsor Overview
Specializations
Hepatic Encephalopathy
Clinical research focuses on overt hepatic encephalopathy and the prevention of encephalopathy-related deterioration in people with cirrhosis. The sponsored studies address treatment areas linked to HE-related hospitalization and delayed decompensation.
- Overt hepatic encephalopathy
- Encephalopathy decompensation in cirrhosis
- HE-related hospitalization
These investigations reflect a therapeutic interest in liver-related neurocognitive complications and their clinical consequences.
Hepatic Impairment
Research activity also includes hepatic impairment, with attention to how reduced liver function affects the handling of therapeutic agents in adults with impaired hepatic function.
- Impaired hepatic function
- Pharmacokinetics in liver dysfunction
- Adult subjects with hepatic impairment
This area supports clinical interest in liver disease populations where altered metabolism and clearance are medically relevant.
Gastroenterology and Liver Disease
The sponsor’s portfolio is centered on gastroenterology and hepatology, particularly conditions arising from chronic liver disease and cirrhosis. The funded studies align with management of complications associated with advanced liver dysfunction.
- Hepatology
- Cirrhosis-associated complications
- Chronic liver disease
Clinical interest is directed toward liver-related disorders that affect neurological status and overall disease burden.
Rifaximin-Based Therapeutic Development
Trial activity includes work involving rifaximin formulations, with emphasis on a soluble solid dispersion approach in liver-compromised populations. The research landscape is tied to treatment development for encephalopathy and hepatic dysfunction.
- Rifaximin formulations
- Soluble solid dispersion
- Liver-compromised patient populations
This focus connects anti-infective gastrointestinal therapy with liver disease management.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION (SSD) TABLETS FOR THE DELAY OF ENCEPHALOPATHY DECOMPENSATION IN CIRRHOSIS (RED-C) |  Belgium Bulgaria France Germany Hungary Italy Poland Spain | Not Recruiting |
| Pharmacokinetic Evaluation of Rifaximin Soluble Solid Dispersion in Adults with Hepatic Impairment | Hungary | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 64 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases1 trial280 other sponsors
- 2.Not possible to specify1 trial220 other sponsors
Partnered Research Centres
64 centres- Address
- Bulevard Nikola Yonkov Vaptsarov 51b, 1407 Sofia
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- 27 Rue du Faubourg Saint-Jacques, 75014 Paris
- Address
- 51 Av Du Mal De Lattre De Tassigny, 94000 Créteil
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Buitenring-Sint-Denijs 30, 9000 Ghent
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Salix Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.